Delivering Biocompatibility

Accord Biomaterials, Inc., based in Ann Arbor, MI, focuses upon the development of Nogen^TM catalytic nitric oxide coatings for blood-contacting medical devices. Nogen coatings address serious complications related to clotting and altered healing, improving performance and reducing total costs of critical medical device interventions. Accord collaborates with the University of Michigan and incubator MC3 Corporation and holds an exclusive license to Nogen technology. Privately-held and venture-backed, Accord is committed to accelerating clinical availability of this revolutionary technology. For more information, contact Kris Aalto via kaalto@accordbiomaterials.com or 734-995-9089.

• ACCORD BIOMATERIALS CLOSES $1M SERIES A TO ADVANCE NITRIC OXIDE MEDICAL DEVICE COATINGS
  
  "Accord Biomaterials, Inc. today announced the closing of their inaugural venture capital round, a $1M Series A financing led by Arboretum Ventures, designed to advance the Nogen^TM nitric oxide technology to improve the biocompatibility of medical devices..."

  > Read the full press (PDF)